Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

All Drugs and Chemicals

Anti-Infective Agents

Fluorodeoxyglucose F18

Deoxyglucose

PET scan

Kathleen Pritchard, MD

Claire Holloway, MD

David McCready, MD

Jim Julian, M.Math.

Mark N Levine, MD

Wendy Shelley, MD

Karen Gulenchyn, MD, PhD

Frances O'Malley, MD

The overall goal of this study is to determine how FDG-PET can be incorporated into the assessment of the axilla in the staging and treatment of women with early stage breast cancer.

A multicentre, prospective, diagnostic accuracy study will be conducted evaluating the ability of positronic emission tomography using fluorodeoxyglucose (FDG-PET) to detect the presence or absence of axillary lymph node metastases in newly diagnosed breast cancer patients with no clinical evidence of spread of disease beyond the breast.

Patients will have histologic confirmation of invasive breast cancer and will have a FDG-PET scan prior to axillary node assessment. All patients will have a sentinel node biopsy if any sentinel nodes can be located. Patients with a positive sentinel node will have an axillary node dissection. The results of the PET will be compared to the reference standard of histologic examination of all excised (sentinel and non-sentinel) axillary lymph nodes which will be referred to as axillary node assessment. Sensitivity, specificity, positive and negative predictive values for PET-FDG will be determined.

PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)

A Prospective Study to Determine the Role of 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)Positron Emission Tomography (PET)in the Assessment of Regional Nodal Spread of Disease in Breast Cancer Patients

Ontario Ministry of Health and Long Term Care

Ontario Clinical Oncology Group (OCOG)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)	NCT00201942	Breast Cancer	PET scan	18 Years -	Ontario Clinical Oncology Group (OCOG)
PET Imaging to Determine the Role of PET in the Assessment of Regional Disease in Breast Cancer (PET PREDICT Trial)	NCT00201942	Breast Cancer	PET scan	18 Years -	Ontario Clinical Oncology Group (OCOG)

Spots Global Cancer Trial Database for positronic emission tomography